Lion Point Capital, LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Lion Point Capital, LP disclosed 19 US equity positions worth $14.7m in its Q2 2025 13F filing. The largest position was FENC at 11.0% of the reported book, followed by ARDX and KINIKSA PHARMACEUTICALS INTL. Against the Q1 2025 filing, it opened 1 new position, added to 0 and reduced 1 among the top 19 holdings.
What did Lion Point Capital, LP own in Q2 2025? Top 19 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | FENC FENNEC PHARMACEUTICALS INC | 11.0% | $1.6m | 195,700 | 0% | held | |
| 2 | ARDX ARDELYX INC | Healthcare | 8.9% | $1.3m | 335,400 | 0% | held |
| 3 | KINIKSA PHARMACEUTICALS INTL | 8.6% | $1.3m | 45,900 | 0% | held | |
| 4 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 7.6% | $1.1m | 26,000 | 0% | held |
| 5 | INSM INSMED INC | Healthcare | 7.3% | $1.1m | 10,650 | -65% | reduced |
| 6 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 7.3% | $1.1m | 79,000 | 0% | held |
| 7 | MIST MILESTONE PHARMACEUTICALS IN | 7.2% | $1.1m | 548,806 | 0% | held | |
| 8 | AVADEL PHARMACEUTICALS PLC | 5.9% | $873.5k | 98,700 | 0% | held | |
| 9 | JSPR JASPER THERAPEUTICS INC | 5.5% | $813.1k | 146,500 | 0% | held | |
| 10 | BENITEC BIOPHARMA INC | 4.9% | $725.4k | 62,000 | 0% | held | |
| 11 | GERN GERON CORP | Healthcare | 4.8% | $705.0k | 500,000 | 0% | held |
| 12 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 4.4% | $649.1k | 46,300 | 0% | held |
| 13 | IRON DISC MEDICINE INC | Healthcare | 3.8% | $561.4k | 10,600 | 0% | held |
| 14 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.5% | $515.1k | 55,000 | 0% | held |
| 15 | RGNX REGENXBIO INC | Healthcare | 3.2% | $474.1k | 57,750 | 0% | held |
| 16 | BHVN BIOHAVEN LTD | Healthcare | 2.2% | $320.3k | 22,700 | 0% | held |
| 17 | MERSANA THERAPEUTICS INC | 1.3% | $190.6k | 644,000 | 0% | held | |
| 18 | SERES THERAPEUTICS INC | 1.3% | $189.3k | 17,038 | – | new | |
| 19 | HUMA HUMACYTE INC | 1.2% | $174.5k | 83,500 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.